COVID 19 Tests
ID: 75A50223C0000Type: Justification
7 AwardsDec 7, 2022
Award #:75A50223C00001-8
View all 7 award notices in Lifecycle →
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR/DAAPPO/ORM HQWashington, DC, 20515, USA

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/77cf9ced70234cbf9d590aafd9af45d3/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.

    Point(s) of Contact
    Junli Collins
    junli.collins@hhs.gov
    Judy Williams
    judy.williams2@hhs.gov
    Files
    Title
    Posted
    JA OTC COVID Tests v.12.pdf
    The Department of Health and Human Services (HHS) is seeking justification for a contract awarded for the procurement of approximately 222 million FDA-approved COVID-19 rapid tests, totaling an estimated value of $710 million. Due to the ongoing national emergency declared for COVID-19, the action falls under an exception for other than full and open competition, allowing expedited acquisition processes. HHS has conducted extensive market research and identified multiple viable vendors to ensure prompt delivery of tests amidst the urgent public health need.
    Lifecycle
    Title
    Type
    COVID 19 Tests
    Currently viewing
    Justification
    J & A for COVID 19 Tests
    Award
    Similar Opportunities
    Serological Assays for the Detection and Characterization of Influenza Viruses
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals for "Serological Assays for the Detection and Characterization of Influenza Viruses." The procurement aims to secure services for performing Hemagglutinin Inhibition (HAI) assays on approximately 6,000 human samples annually, with the potential for surge support up to 10,500 tests, alongside the development of new high-throughput serology assays. This initiative is crucial for enhancing the CDC's capabilities in monitoring and responding to influenza outbreaks. Interested parties should note that the solicitation has been reopened, with key deadlines extended, and are encouraged to contact Jennifer Gartzke at jgartzke@cdc.gov for contractual inquiries. The contract will span a base period of 12 months with four additional option years, and all work must comply with Section 508 accessibility standards.
    Hologic Covid Testing Supplies
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is seeking to procure Hologic COVID-19 testing supplies for the Tidewater Contracting Division. This sole source acquisition, valued at $1,697,962.00, is essential for maintaining the functionality of existing analyzers at NH Jacksonville, as Hologic is the only vendor capable of providing the necessary compatible assays and reagents. The procurement is critical for ongoing COVID-19 testing efforts, and market research has confirmed that no substitute items are available, thus justifying the sole source approach. Interested parties can reach out to Jessica Horst at jessica.l.horst5.civ@health.mil or Annette Jackson at annette.d.jackson2.civ@health.mil for further information.
    GMP Manufacturing of CDC FluSC2 Multiplex EUA Kit
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), has awarded a contract for the GMP manufacturing of the CDC FluSC2 Multiplex EUA Kit to Biosearch Technologies, Inc. This contract, valued at $399,993, entails the production of 1,020 vials of oligonucleotide primers and probes, adhering to Good Manufacturing Practices (GMP) as defined under 21 CFR 820, with a required delivery date of September 25, 2023. The specific internal BHQnova quencher design of the probes is critical for the diagnostic assay, which has received Emergency Use Authorization (EUA) from the FDA, and no other suppliers have been identified that can meet these stringent requirements. For further inquiries, interested parties may contact Mark Draluck at syq1@cdc.gov or Devin Barich at uca9@cdc.gov.
    Laboratory Response Network Support Modification Justification
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking support for the Laboratory Response Network through a modification justification. This procurement involves an exception to the fair opportunity process, as detailed in the attached justification document, which outlines the specific requirements and objectives for this contract. The services sought are critical for enhancing the CDC's capabilities in managing public health emergencies and laboratory response efforts. Interested parties can reach out to Luci Cason at reo3@cdc.gov for further information regarding this opportunity.
    Notice of Intent to Sole Source – Werfen USA, LLC
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), intends to award a sole source contract to Werfen USA, LLC for the procurement of kits and reagents essential for patient care testing, specifically for use with the ACL TOP 350 and 750 analyzers. This procurement, valued at approximately $570,000 over a base year and two option years (January 1, 2026, to December 31, 2028), is critical as the reagents are uniquely validated for the existing instruments, ensuring continuity in patient care and research protocols. The acquisition will be conducted under the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for increased procedural flexibility and efficiency. Interested parties may submit comments regarding this notice to Ryssa Nix at ryssa.nix@nih.gov by the close date of December 23, 2025, at 12 PM EST.
    R--RADx Award Management
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking sources for the RADx Award Management through a Special Notice. This procurement aims to identify qualified entities that can provide management consulting services related to the RADx initiative, which is crucial for enhancing COVID-19 testing capabilities and supporting public health efforts. Interested parties are encouraged to reach out to Melanie D. Suarez at melanie.suarez@nih.gov or call +1 301 827 7558 for further information regarding this opportunity. The notice emphasizes the importance of professional program management and support services in achieving the objectives of the RADx program.
    Notice of Intent to Sole Source Modification of Contract to Quest Diagnostics, Inc.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), intends to negotiate a non-competitive modification to an existing contract with Quest Diagnostics, Inc. This modification aims to expand the scope of the contract to include access to de-identified antibody results from previously tested specimens, focusing on individuals with immunocompromising conditions as part of the CDC's Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) Study. The contract modification is crucial for estimating the prevalence of SARS-CoV-2 infections and vaccinations across various demographics and geographic locations, utilizing existing data rather than incurring additional costs for new specimen collection. Interested parties may submit responses to this notice within 15 days to the primary contact, Liz Cole-Greenblatt, at qst7@cdc.gov, although the government retains discretion over whether to pursue competitive procurement.
    TX Bio Mermade PMA
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), intends to award a sole source firm fixed price purchase order to Tx. Bio LLC for Equipment Maintenance Services related to the TX Bio Mermade PMA. This procurement is necessary as Tx. Bio LLC holds exclusive maintenance agreements for the equipment in question, which is critical for ongoing research and development in biotechnology. Interested parties are invited to express their interest and capability to respond to this requirement, with all responses due by COB on December 30, 2025, to contract specialist Aminah A. Gary at uuu0@cdc.gov. The government reserves the right to determine whether to proceed with a competitive procurement based on the responses received.
    66--TEST KIT, LP
    Dept Of Defense
    The Department of Defense, specifically the Department of the Navy, is seeking to procure two test kits under the presolicitation notice titled "66--TEST KIT, LP." The procurement involves the delivery of these kits to designated distribution centers in New Cumberland, PA, and Tracy, CA, with the Government indicating that the rights to use the necessary data for purchasing or repairing this part from additional sources are not owned by them, making reverse engineering uneconomical. This procurement is critical for ensuring the availability of specialized electrical and electronic properties measuring and testing instruments, which play a vital role in defense operations. Interested parties are encouraged to contact Danielle Dell Isola at (771) 229-0057 or via email at DANIELLE.DELLISOLA@NAVY.MIL for further details, and they have 45 days to express their interest or submit proposals following the notice publication.
    Japanese Encephalitis Vaccine
    Health And Human Services, Department Of
    The Department of Health and Human Services is seeking suppliers for the Japanese Encephalitis Vaccine, specifically the Ixiaro brand or an equivalent product. The procurement involves a requirement for 800 syringes of the vaccine, identified by NDC 42515-0002-01 and NSN: 6505-01-607-7018, which is critical for immunization against Japanese Encephalitis, a serious viral infection. Interested vendors should note that the place of performance is Perry Point, Maryland, and they can reach out to Tim Bouchelle at Timothy.Bouchelle@hhs.gov or by phone at 443-947-6039 for further inquiries. This opportunity is categorized under the Pharmaceutical and Medicine Manufacturing industry, with no set-aside restrictions.